Epigenetics Diagnostics Market Size, Share, Report 2023-2032
The global epigenetics diagnostics market was estimated at USD 12.87 billion in 2022 and it is expected to surpass around USD 52.61 billion by 2032, poised to grow at a CAGR of c from 2023 to 2032. The epigenetics diagnostics market in the United States was accounted for USD 3.14 Billion in 2022.
Key Pointers
Report Scope of the Epigenetics Diagnostics Market
| Report Coverage | Details |
| Revenue Share of North America in 2022 | 39% |
| CAGR of Asia Pacific from 2023 to 2032 | 17.23% |
| Revenue Forecast by 2032 | USD 52.61 billion |
| Growth Rate from 2023 to 2032 | CAGR of 52.61% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Companies Covered | Roche Diagnostics, Thermo Fisher Scientific, Inc., Eisai Co. Ltd., Novartis AG, Element Biosciences, Inc., Dovetail Genomics LLC., Illumina, Inc., ValiRx Plc., Abcam plc. |
The high growth is mainly attributed to the increase in investment, funds, and approvals for epigenetics research & development, growing applications of epigenetics in drug discovery & development, and increased affordability of genome sequencing. Epigenetics has exhibited its application potential in non-oncology conditions, thus creating tremendous opportunities for market growth. Epigenetic pathways may be directly or indirectly involved in a variety of cancers, Cardiovascular Disorders (CVDs), reproductive problems, autoimmune diseases, and ailments that affect cognitive function.
The function of these epigenetic pathways can be influenced by external stimuli including the causative agents, such as heavy metals, pesticides, cigarette smoke, hormones, radiation, viruses, environmental factors, and essential nutrients. Increasing awareness regarding epigenetic testing and the increasing demand for such kits and assays is one of the crucial factors in the growth of this market. Increased healthcare R&D spending across the globe is also anticipated to fuel market expansion over the forecast period. For instance, according to the WHO report published in April 2023, the weighted average health GERD as% of GDP increased the most in high-income nations (0.25%) compared to the previous analysis (0.21%).
This can be attributed to the rise of GERD in several of these high-income nations, with the Republic of Korea reporting the biggest rise (from USD 3.8 billion to USD 4.5 billion in 2020), followed by Greece (from USD 513 million to USD 598 million in 2020). Over 15% was reported as an upsurge in both nations. In addition, for instance, in February 2021, the International Cancer Genome Consortium (ICGC) launched the ICGC ARGO Data Platform, a significant step forward after the ICGC 25K Data Portal. ARGO is a global initiative to promote cancer genetics by providing superior-quality clinical, genomic, and molecular data to worldwide researchers.
The spread of the COVID-19 virus created tremendous opportunities for epigenetics researchers. A study conducted by the researchers, wherein they performed DNA methylation on monocytes in the peripheral blood samples obtained from COVID-19 patients, demonstrated the complex relationship between the changes that occurred during myeloid differentiation and DNA methylation changes in COVID-19 patients. Increasing government support and funding for epigenetic research will encourage companies to develop novel epigenetic products and boost market growth in the near future.
Product Insights
Based on product, the market is segmented into reagents, kits, instruments, enzymes, and services. The reagents segment accounted for the largest revenue share of 32% in 2022. The large share of this segment is mainly attributed to the high usage of reagents in epigenetic research studies. The two main categories of reagents used in epigenetics are histone and DNA modifiers. Epigenetics is the study of persistent, maybe reversible changes in gene expression that take place without altering the DNA sequence permanently but that still transfer from one generation to the next generation. Without any changes to the DNA, epigenetically controlled genes can be triggered or suppressed.
DNA methylation, RNA regulation, and histone modification are the three main epigenetic processes that have been the subject of comprehensive research. These mechanisms are crucial for the control of genes. On the other hand, the kits segment is anticipated to record the highest CAGR of over 15.4% during the forecast period. Epigenetic kit demand is fueled by trends, such as a rise in the cases of chronic diseases, a growing aging population, and an increase in the application of epigenetic treatments. In addition, the growing awareness among people along with an increasing number of companies involved in the development of advanced kits will push the segmental growth further.
Technology Insights
Based on the technology, the market is segmented into DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microRNA modification, and chromatin structures. The oncology segment accounted for the largest revenue share of 70% in 2022. DNA is treated biochemically and enzymatically by methylation-sensitive enzymes as part of the DNA methylation process, which is used to prepare DNA for methylation analysis. The DNA methylation method holds great promise for unraveling the functional processes behind complicated disorders as well as developing individualized medicines. The rising demand for DNA methylation techniques is responsible for the market growth. Technology advancements are making it possible to evaluate locus-specific DNA methylation on a genome-wide scale more often.
The histone acetylation segment is anticipated to expand at the fastest CAGR of 15.82% from 2023 to 2032 due to its improved efficacy as a result of the development of innovative methods. Numerous studies have suggested that histone acetylation may have therapeutic benefits in conditions, such as solid tumors, inflammation, leukemia, and viral infection. Histone Acetyltransferase 1 (HAT1), General Control Nonrepressible 5 (GNC5), CREB-binding protein (CBP), P300/CBP-binding protein (PCAF), MYST family, P300, TAFII250, and Rtt109 are the HAT subfamilies that have received the most attention to date. It has commonly been claimed that HAT1 contributes to carcinogenesis. With such wide therapeutic potential applications, the market is likely to flourish during the forecast period.
Application Insights
On the basis of applications, the global industry has been further categorized into oncology and non-oncology. The oncology application segment accounted for the largest revenue share of 70% in 2022. Currently, cancer is the major area for epigenetics research. With the increasing number of cancer incidences, the market for cancer-related epigenetic diagnosis is likely to grow. As per the American Cancer Society, the estimated number of new cancer cases in the U.S. in 2022 was 1.9 million with around 609,360 deaths caused due to cancer.
On the other hand, the non-oncology application segment is projected to grow at the fastest CAGR of 15.75% during the forecast years. There has been a growing interest in epigenetics studies in the non-oncology disease indication. The non-oncology applications of epigenetics include neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, etc., and developmental disorders, such as ASDs, CVDs, metabolic disorders, and many others. The increasing usage of epigenetics in non-oncology indications will further boost the growth of this segment.
Regional Insights
North America dominated the market with a revenue share of 39% in 2022. The large share is mainly attributed to government support and the presence of major companies. High awareness among people, advanced medical infrastructure, and high R&D expenditure are some of the other factors that support the market growth in the region. Moreover, the high prevalence of chronic diseases and increasing investment by market participants for the development of epigenetics will boost regional growth further. For instance, Chroma Medicine, Inc. (Chroma), a brand-new genomic medicine business that pioneered epigenetic editing, started with USD 125 million in investment in November 2021 to treat a variety of disorders and become the most commonly used technology for gene regulation.
The market in the Asia Pacific region is projected to grow at the fastest CAGR of 17.23% from 2023 to 2032. The Asia Pacific market is expected to rise owing to increasing investment in research & development activities by the government and growing incidences of cancer. For instance, in 2022, the WHO South-East Asia Region recorded 1.4 million cancer-related fatalities and approximately 2.2 million new cases, accounting for over one out of every ten deaths in the region. Lung cancer caused 10.6% of cancer-related fatalities, followed by breast cancer (9.4%), cervical cancer (8%), liver cancer (6.6%), and oral cavity cancer at 6.4%. The growing adoption of epigenetics in developing economies will boost regional market growth during the forecast period.
Epigenetics Diagnostics Market Segmentations:
By Product
By Application
By Technology
By Regional
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers